Imagine waking up one morning to find out that a deadly bacteria could strike without warning, leaving devastation in its wake. Meningococcal meningitis is that kind of nightmare—a disease so swift and severe that it can claim lives within hours. Yet, despite its terrifying reputation, meningococcal vaccines aren’t recommended for everyone. Why? It’s a question that’s both practical and deeply personal, especially for those who’ve witnessed its horrors firsthand. But here’s where it gets controversial: Is it a matter of cost, risk, or something else entirely? Let’s dive in.
A reader, H.R., recently asked why meningococcal vaccines aren’t recommended for people over 23. Their concern is rooted in a chilling experience: working in an emergency room where two patients died from meningococcal meningitis, forcing the entire staff to undergo prophylactic treatment. H.R.’s fear is palpable, and their question cuts to the heart of public health decision-making. Are we underestimating the risk, or is there a bigger picture we’re missing?
Meningococcus, or Neisseria meningitidis, is indeed a formidable pathogen. Even survivors often face long-term complications, making prevention critical. So, why isn’t vaccination universal? The answer lies in the delicate balance between benefit, risk, and cost. Vaccines are recommended when their benefits outweigh the risks and when the cost of intervention aligns with societal priorities. For meningococcal vaccines, while highly safe and effective, the disease’s rarity limits their cost-effectiveness to high-risk groups.
And this is the part most people miss: The disease is incredibly rare, with approximately 1 case per 400,000 people annually before vaccination campaigns. Today, that number has dropped to about 1 case per million. For healthy adults not living in high-exposure settings like college dormitories, the cost of preventing a single case can soar to $10 million or more. That’s why recommendations focus on adolescents, young adults in close quarters, and those with specific risk factors like immune deficiencies, HIV, or spleen issues.
There are two primary vaccines: MenACWY (for serogroups ACWY) and MenB (for serogroup B). MenACWY is recommended for all adolescents, ideally starting at ages 11-12 with a booster before college. MenB, given in two doses six months apart between ages 16-18, is still under discussion for broader recommendations. Lab workers exposed to the bacteria and individuals on certain medications (like eculizumab) are also prioritized.
Here’s the kicker: While the vaccine is a no-brainer for high-risk groups, its value for healthy adults is less clear. I vaccinated my child before college for peace of mind, but I’ve opted out for myself due to my low risk. This decision reflects the vaccine’s high cost and the disease’s low prevalence—a success story partly due to targeted vaccination efforts.
But here’s where it gets controversial: Should we prioritize individual peace of mind over societal cost-effectiveness? If a vaccine is safe and effective, why not make it available to everyone, regardless of risk? And what happens during an outbreak? Public health officials may broaden recommendations, but that’s a reactive measure, not a preventive one.
So, what do you think? Is the current approach to meningococcal vaccination fair, or should we rethink who gets protected? Let’s start the conversation—because when it comes to health, every perspective matters.
